Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15400478 | 0.94 | GRIN2D (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12781258 | 0.86 | CKS1B (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15401408 | 0.86 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15401386 | 0.84 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15400191 | 0.82 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29668733 | 0.81 | GAA (0.65) | L3MBTL1GAATGM2KMT2AMEN1 | |
| SCHEMBL20339488 | 0.81 | HTR3E (0.63) | GRIN2BL3MBTL1GAATGM2KMT2A | |
| SCHEMBL27913890 | 0.81 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19994396 | 0.80 | ALOX5 (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15401261 | 0.79 | GRIN2D (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102666489-B | Sphingosine kinase inhibitors | MERCK PATENT GMBH | 2014-07-23 | — | — | CN | disclosed |
| US-8748420-B2 | Pyridinylcarboxylic acid derivatives as fungicides | BAYER CROPSCIENCE AG (DE) | 2014-06-10 | — | — | US | disclosed |
| US-20140066442-A1 | Pyridinylcarboxylic Acid Derivatives as Fungicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8604040-B2 | Pyridinylcarboxylic acid derivatives as fungicides | BAYER CROPSCIENCE AG (DE) | 2013-12-10 | — | — | US | disclosed |
| CN-102666489-A | Sphingosine kinase inhibitors | MERCK PATENT GMBH | 2012-09-12 | — | — | CN | disclosed |
| US-20120065197-A1 | Pyridinylcarboxylic Acid Derivatives as Fungicides | BAYER CROPSCIENCE AG (DE) | 2012-03-15 | — | — | US | disclosed |
| EP-2310381-A1 | 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER | Novartis AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009150230-A1 | 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
| EP-1871762-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006113704-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065197-A1 | Pyridinylcarboxylic Acid Derivatives as Fungicides | PNPO, CYP1A1, CHRM1 | GRIN2D 702/4885GRIN3B 1082/4885GRIN1 143/4885 |
| US-20140066442-A1 | Pyridinylcarboxylic Acid Derivatives as Fungicides | PNPO, CYP1A1, CHRM1 | GRIN2D 638/4885GRIN3B 905/4885GRIN1 98/4885 |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | GRIN2D 334/4885GRIN3B 250/4885GRIN1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.